ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Delayed Calcineurin Inhibitor Introduction and Long Term Renal Outcomes in Liver Transplant Recipients Receiving Basiliximab Induction.

N. Lange,1,2 D. Salerno,1 C. Sammons.2

1Department of Pharmacy, Weill Cornell Medical Center, New York, NY
2Department of Pharmacy, Columbia University Irving Medical Center, New York, NY

Meeting: 2017 American Transplant Congress

Abstract number: D202

Keywords: Liver transplantation, Monoclonal antibodies, Renal dysfunction

Session Information

Session Name: Poster Session D: Liver: Immunosuppression and Rejection

Session Type: Poster Session

Date: Tuesday, May 2, 2017

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall D1

BACKGROUND Basiliximab may be used to delay the initation of calcineurin inhibitors (CNI) in patients with renal injury after liver transplantation (LT). The optimal time to introduce a CNI to portend favorable long-term renal outcomes is unknown.

METHODS All adults transplanted between 01/07-12/15 who received basiliximab were included in a retrospective analysis. We evaluated 90 day renal outcomes stratified both by severity of renal injury and degree of achieved renal recovery (=1-[SCr at CNI initiation]/[max post-LT SCr]). The primary outcome was the percentage of patients who remained within Acute Kidney Injury Network (AKIN) criteria at 90 days post-LT.

RESULTS 200 LT recipients were included. Three-group stratification occurred by percent renal recovery at the time of CNI initiation: 0-33%, 34-66%, 67-100%. No differences in baseline characteristics were identified, except MELD scores, which were highest in Group 3 (22 vs. 24 vs. 27, p<0.01). For the primary outcome, 98 (49%) patients met AKIN criteria at baseline vs. 24 (12%) patients at 90 days post-LT; no between-group differences were observed. At 90 days post-LT, patients with 67-100% renal recovery at the time of CNI initiation (Group 3) had significantly greater eGFR (66 vs. 60 vs. 88 mL/min, p<0.02). No between-group differences were observed in CNI concentrations at any time point.

CONCLUSION Patients with the largest percent of renal recovery at the time of CNI initiation had the greatest eGFR at 90 days post-LT, despite having higher MELD scores at baseline.

Characteristic Group 1 (0-33% recovery) Group 2 (34-66% recovery) Group 3 (67-100% recovery) p-value
Baseline AKIN class, n (%) 0.17
None 53 (59) 40 (44) 9 (47)
1 15 (17) 22 (24) 4 (21)
2 13 (14) 22 (24) 2 (11)
3 9 (10) 7 (8) 4 (21)
Remain in AKIN at 90 days, n (%) 8 (9) 14 (15) 2 (11) 0.43

CITATION INFORMATION: Lange N, Salerno D, Sammons C. Delayed Calcineurin Inhibitor Introduction and Long Term Renal Outcomes in Liver Transplant Recipients Receiving Basiliximab Induction. Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Lange N, Salerno D, Sammons C. Delayed Calcineurin Inhibitor Introduction and Long Term Renal Outcomes in Liver Transplant Recipients Receiving Basiliximab Induction. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/delayed-calcineurin-inhibitor-introduction-and-long-term-renal-outcomes-in-liver-transplant-recipients-receiving-basiliximab-induction/. Accessed June 3, 2025.

« Back to 2017 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences